SCOTUS
Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
DecidedJun 4, 2026
9-0decision
Source: CourtListener.
Court rules generic drugmaker's label and marketing did not illegally encourage use of patented drug method
Impact5/10
What it does
The Court held that a generic drug manufacturer's statements — including its abbreviated drug label, patient information leaflet, website, and investor press releases — did not amount to "active steps" to encourage doctors or pharmacists to use the drug for a patented purpose. To survive a motion to dismiss, a patent holder must plausibly allege that the generic manufacturer affirmatively encouraged infringing use, not merely that healthcare providers could have read the statements as instructions to infringe. Omissions, vague language, and conduct that simply follows legal requirements or standard industry practice cannot form the basis of an active inducement claim.
Who benefits
Generic drug manufacturers who market drugs using "skinny labels" — abbreviated labels that carve out still-patented uses — and who follow standard labeling laws and industry practices without expressly promoting patented uses.
Who is affected
Brand-name pharmaceutical companies holding method-of-use patents whose drugs are subject to generic competition, who seek to hold generic manufacturers liable when doctors prescribe the generic for a patented use.
Practical impact
Generic drug manufacturers using skinny labels can now point to this ruling when defending against induced-infringement lawsuits, as long as their labeling and marketing follow legal requirements and standard industry practice rather than affirmatively promoting patented uses. Brand-name drug companies will face a higher bar when trying to sue generic competitors for induced infringement — they must identify specific, affirmative statements or actions designed to encourage the patented use, not just argue that doctors could have inferred encouragement from vague or legally required language. Courts reviewing similar complaints must focus on whether the generic manufacturer actively encouraged infringement, not on how a doctor might have interpreted the statements.
Majority reasoning
The majority held that the legal standard for "active inducement" of patent infringement requires affirmative steps designed to encourage infringement — not merely statements that someone could passively read as an instruction to infringe. The Court reasoned that several of Hikma's statements had an obvious alternative explanation: they were required by law (the generic label must mirror the brand label except for carved-out uses) or reflected normal industry practice (calling a drug the "generic equivalent" of a brand-name drug). The majority further held that omissions — such as not mentioning that the drug's approved use was limited to the less common condition — cannot count as "active steps," because inducement law requires affirmative conduct, not silence. The Court found the remaining statements (a side-effects warning, a disclaimer that medicines are sometimes prescribed for other purposes, a broad therapeutic category description, an "AB" equivalence rating, and investor-facing sales figures) too vague and too many inferential steps removed from any actual encouragement of infringement to meet the plausibility standard required to proceed to trial.
Constitutional question
Did Hikma Pharmaceuticals' skinny label, website, and press releases — taken together — constitute "active inducement" of patent infringement under 35 U.S.C. §271(b), sufficient to survive a motion to dismiss?
Precedent changed
The Court did not overrule any prior precedent, but it explicitly rejected the Federal Circuit's growing trend of asking whether medical providers could plausibly read statements as instructions to infringe, reaffirming that the correct question is whether the defendant actively encouraged infringement.